pment services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, the realization of savings from the Company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
Financial Exhibits FollowCOVANCE INC.CONSOLIDATED INCOME STATEMENTSFOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2012 AND 2011(Dollars in thousands, except per share data)Three Months Ended December 31Years Ended December 312012201120122011(UNAUDITED)Net revenues$
562,180$
532,478$ 2,180,621$ 2,095,938Reimbursable out-of-pocket expenses46,96449,907185,138140,508Total revenues609,144582,3852,365,7592,236,446Costs and expenses: Cost of revenue395,841371,8521,570,2231,467,051 Reimbursable out-of-pocket expenses46,96449,907185,138140,508 Selling, general and administrative92,82395,752358,854343,044 Depreciation and amortization30,42325,923117,708105,214 Goodwill impairment charge--17,959-Total costs and expenses566,051(a)543,434(c)2,249,882(b)2,055,817(d)Income from operations43,093(a)38,951(c)115,877(b)180,629(d)Other expense, net: Interest expense, net1,1533393,5061,979 Foreign exchange transaction loss, net1733561,4741,248 Impairment of equity investment-12,1197,37312,119 Gain on sale of investment--(1,459)- Loss on sale of business--169-Other expense, net1,32612,814(c)11,06315,346(d)Income before taxes and equity investee earnings41,767(a)26,137(c)104,814(b)165,283(d)Taxes on income7,870(a)5,172(c)10,099(b)33,574(d)
'/>"/>
SOURCE Covance Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine technology :1.
Covance To Present At The William Blair 32nd Annual Growth Stock Conference2.
Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million3.
Covance to Present at the Morgan Stanley Global Healthcare Conference4.
Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million5.
Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference6.
Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events7.
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.8.
Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 20129.
Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 201210.
Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter11.
CryoLife Reports Record Quarterly Revenues in First Quarter of 2012